Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectivelyEnded 2024 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback